Summary of adverse events, serious adverse events, and discontinuations due to adverse events
| Lumiracoxib 200mg od (n = 487) | Lumiracoxib 400mg od (n = 491) | Celecoxib 200mg od (n = 481) | Placebo (n = 243) | |
|---|---|---|---|---|
| Results are shown as No . | ||||
| AE, adverse event GI, gastrointestinal od, once daily SAE, serious adverse event. | ||||
| Patients with SAEs | 12 2.5 | 14 2.9 | 14 2.9 | 8 3.3 |
| Patients with AEs | 280 57.5 | 288 58.7 | 256 53.2 | 124 51.0 |
| Discontinuations due to AEs | 42 8.6 | 43 8.8 | 47 9.8 | 21 8.6 |
| Discontinuations due to GI AEs | 18 3.7 | 22 4.5 | 19 4.0 | 6 2.5 |